Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FleuryBSP:FLRY3 -0.33%90 Days Sales Outstanding is 80.76 as of Jun. 2026, which is 23% above its 10-year median of 65.87. GuruFocus rates BSP:FLRY3 with a GF Score™ of 90/100 and a GF Value™ of R$17.58 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Fleury ranks worse than 61.19% on this metric.
Fleury's average Accounts Receivable for the
three
months ended in Jun. 2026 was R$2,050 Mil. Fleury's Revenue for the
three
months ended in Jun. 2026 was R$2,317 Mil.
Hence, Fleury's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 80.76.
The historical rank and industry rank for Fleury's Days Sales Outstanding or its related term are showing as below:
BSP:FLRY3'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.49 Med: 65.87 Max: 79.99
Current: 79.99
During the past 13 years, Fleury's highest Days Sales Outstanding was 79.99. The lowest was 53.49. And the median was 65.87.
BSP:FLRY3's Days Sales Outstanding is ranked worse than 61.19% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.59
vs BSP:FLRY3: 79.99
Fleury's Days Sales Outstanding
declined
from Jun. 2025 (82.23) to Jun. 2026 (80.76).
Fleury (BSP:FLRY3) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Fleury Days Sales Outstanding Related Terms
Fleury Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Fleury's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:FLRY3 vs TMO, DHR, NTRA: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, Fleury's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fleury Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fleury's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Fleury's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fleury (BSP:FLRY3) has a Days Sales Outstanding of 80.76 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Fleury and its competitors. This is 23% above median its historical median of 65.87. Over the past decade, Fleury's Days Sales Outstanding has ranged from 53.49 to 79.99. According to the industry distribution chart, Fleury ranks #123 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 61.2%.
Is Fleury's Days Sales Outstanding too high?
Fleury's current Days Sales Outstanding of 80.76 is 23% above median its 10-year median of 65.87. Over the past 10 years, this metric has ranged from a low of 53.49 to a high of 79.99. The Medical Diagnostics & Research industry median Days Sales Outstanding is 67.59. Fleury's value of 80.76 is 19.5% above this industry median. Based on the distribution chart, Fleury ranks #123 out of 201 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Fleury has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fleury's Days Sales Outstanding compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Fleury ranks #123 out of 201 companies for Days Sales Outstanding. This places Fleury in the lower half of its industry. The industry median Days Sales Outstanding is 67.59. Fleury's value of 80.76 is 19.5% above this benchmark. Historically, Fleury's own Days Sales Outstanding has ranged from 53.49 to 79.99 over the past decade. While the company's 10-year median is 65.87 vs. the industry median of 67.59, Fleury has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.59, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fleury's current Days Sales Outstanding of 80.76 is 19.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Fleury and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fleury's current Days Sales Outstanding is 80.76, which is 23% above median its own 10-year median of 65.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fleury stock overvalued right now?
Based on GuruFocus' analysis, Fleury (BSP:FLRY3) is currently considered Modestly Overvalued. The stock's GF Value™ is R$17.58, compared to a current price of R$21.38 — trading 21.6% above its estimated fair value. The current Days Sales Outstanding is 80.76, which is 23% above median its 10-year median of 65.87 and 19.5% above the Medical Diagnostics & Research industry median of 67.59. Fleury's overall GF Score™ is 90/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Fleury (BSP:FLRY3), the current Days Sales Outstanding is 80.76 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fleury (BSP:FLRY3) Overvalued in 2026?
Based on GuruFocus' analysis, Fleury stock appears to be overvalued.
The current stock price of R$21.38 is trading 21.6% above its estimated GF Value™ of R$17.58.
GuruFocus considers Fleury to be Modestly Overvalued.
Key valuation signals for BSP:FLRY3:
Days Sales Outstanding: 80.76 (23% above median its 10-year median of 65.87)
GF Value™: R$17.58 vs. price of R$21.38 (21.6% above fair value)
Industry Position: 19.5% above the Medical Diagnostics & Research median (#123 of 201)
No single metric tells the full story. See the BSP:FLRY3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fleury SA is engaged in the provision of medical services in the diagnostic, laboratory support (Lab-to-Lab), infusions, clinical analysis, health management, medical care, orthopedics and ophthalmology, fertility, infusion areas and toxicological exams, among others. The company offers diagnostic medicine through physical service units and mobile diagnostic services for consumers. It also provides diagnostic support services to laboratories and hospitals. In addition, the company operates clinics and services in areas such as infusion therapy, orthopedics, ophthalmology, reproductive medicine, and oncology. It has two reportable business segments: Diagnostic Medicine and Integrated Medicine. The maximum revenue is generated from the Diagnostic Medicine Segment.
90GF Score
Get the complete analysis for BSP:FLRY3
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:FLRY3 has been successfully added to your 
